Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus Biopharma Corporation (ABUS) announced participation in investor conferences to discuss its progress in developing a functional cure for chronic hepatitis B virus infection.
03/08/2024 - 07:30 AM
WARMINSTER, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in Miami, FL:
Barclays 26th Annual Global Healthcare Conference : Formal Presentation on March 12, 2024 at 2:05 pm ETJefferies Biotech on the Bay Summit: March 13, 2024To access the live webcast of the presentation at the Barclays 26th Annual Global Healthcare Conference please visit: https://investor.arbutusbio.com/events-presentations . An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729) and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com .
Contact Information
Investors and Media lcaperelli@arbutusbio.com
When will Arbutus Biopharma Corporation participate in the Barclays 26th Annual Global Healthcare Conference?
Arbutus Biopharma Corporation will participate in the Barclays 26th Annual Global Healthcare Conference on March 12, 2024, at 2:05 pm ET.
What is the focus of Arbutus Biopharma Corporation's research?
Arbutus Biopharma Corporation is focusing on developing a functional cure for chronic hepatitis B virus infection.
Where can investors access the live webcast of the presentation at the Barclays 26th Annual Global Healthcare Conference?
Investors can access the live webcast of the presentation at the Barclays 26th Annual Global Healthcare Conference on the Arbutus website.
What is the date of the Jefferies Biotech on the Bay Summit?
The Jefferies Biotech on the Bay Summit will take place on March 13, 2024.
ABUS Rankings
#3662 Ranked by Stock Gains
ABUS Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Warminster
About ABUS
arbutus biopharma corporation (nasdaq:abus) is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis b infection, a disease of the liver caused by hepatitis b virus (hbv). we are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the hbv treatment landscape and cure hepatitis b virus disease. in addition to our hbv assets, we are developing a pipeline of programs that leverage our expertise in rna interference (rnai) therapeutics and our lipid nanoparticle (lnp) technology.
